FindTrial
Sign In

Risk factors and predictive model for extracorporeal circuit life in patients treated with artificial liver support system

Risk factors and predictive model for extracorporeal circuit life in patients treated with artificial liver support system

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075356
Enrollment
Unknown
Registered
2023-09-01
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe liver disease

Interventions

Case series:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) History of chronic HBV infection, total bilirubin = 12mg/dL (205umol/L), prothrombin time international normalized ratio (PT-INR) unlimited (2) Artificial liver therapy with citric acid anticoagulation was planned, and the artificial liver therapy mode was sequential plasma exchange with dual plasma molecular adsorption system (DPMAS + PE) (3) Age 18-75 years old, male or female. (4) Agree to participate in this study.

Exclusion criteria

Exclusion criteria: (1) The patient has the following conditions: history of malignancy or suspected malignancy, planned to receive non-liver organ transplantation or has undergone any organ transplantation. (2) Citric acid anticoagulation contraindication: shock, or uncorrected hypoxemia.

Design outcomes

Primary

MeasureTime frame
Extracorporeal circuit failure;—

Countries

China

Contacts

Public ContactYuanji Ma

Center of Infectious Diseases, West China Hospital of Sichuan University

maxe.doc@163.com+86 189 8060 6465

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026